Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Feb 3;7(2):e525.
doi: 10.1038/bcj.2017.6.

The role of the extracellular matrix in primary myelofibrosis

O Leiva  1 , S K Ng  1 , S Chitalia  1 , A Balduini  2   3 , S Matsuura  1 , K Ravid  1
Affiliations
Review

The role of the extracellular matrix in primary myelofibrosis

O Leiva et al. Blood Cancer J. .

Abstract

Primary myelofibrosis (PMF) is a myeloproliferative neoplasm that arises from clonal proliferation of hematopoietic stem cells and leads to progressive bone marrow (BM) fibrosis. While cellular mutations involved in the development of PMF have been heavily investigated, noteworthy is the important role the extracellular matrix (ECM) plays in the progression of BM fibrosis. This review surveys ECM proteins contributors of PMF, and highlights how better understanding of the control of the ECM within the BM niche may lead to combined therapeutic options in PMF.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Schematic presentation of major components in ECM derived from MKs and involved in PMF progression. The parentheses include reference numbers corresponding to the illustrated pathway. BM, bone marrow; bFGF, basic fibroblast growth factor; ECM, extracellular matrix; IL-1β, interleukin-1 beta; LOX, lysyl oxidase; MK, megakaryocyte; MMP, matrix metalloproteinase; MSC, mesenchymal stromal cell; PDGF-R, PDGF receptor; TGF-β, transforming factor beta; TIMP, tissue inhibitor of metalloproteinases; TSP-1, thrombospondin-1; PDGF, platelet derived growth factor; VEGF, vascular endothelial growth factor.
See this image and copyright information in PMC

References

    1. Tefferi A, Vardiman JW. Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms. Leukemia 2008; 22: 14–22. - PubMed
    1. Barosi G. Essential thrombocythemia vs. early/prefibrotic myelofibrosis: why does it matter. Best Pract Res Clin Haematol 2014; 27: 129–140. - PubMed
    1. Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 2016; 127: 2391–2405. - PubMed
    1. Visani G, Finelli C, Castelli U, Petti MC, Ricci P, Vianelli N et al. Myelofibrosis with myeloid metaplasia: clinical and haematological parameters predicting survival in a series of 133 patients. Br J Haematol 1990; 75: 4–9. - PubMed
    1. Tefferi A. Myelofibrosis with myeloid metaplasia. N Engl J Med 2000; 342: 1255–1265. - PubMed

Publication types